Arrowhead Research, the parent firm of Calando Pharmaceuticals, said last week that it has received notice from the Nasdaq Stock Market that it does not comply with the exchange's $1 minimum bid requirement for continued listing.

The company said it has been given 180 days, until March 15, 2010, to regain compliance by maintaining a minimum closing bid price of $1 per share for 10 consecutive business days. If it does not regain compliance, Arrowhead's stock will be subjected to delisting, the company said.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.